What's the Difference Between Weight Loss Medications like Ozempic & Mounjaro?
Many of Zealthy’s weight loss program members will take GLP-1 medications to achieve lasting weight loss. Some use brand name medications like Wegovy, Zepbound, or Mounjaro, while others use compound medications like Semaglutide or Tirzepatide, the active ingredients in these brand name GLP-1 medications.
The key reason that Zealthy members might move forward with compound medications is because their insurance does not approve covering their medication, and Zealthy weight loss members are able to get compound semaglutide (the active ingredient in Wegovy and Ozempic) for as little as $130/month, compared to over $1,000 for brand name medications.
Here are the key differences and explanations of common GLP-1 medications.
Ozempic (Semaglutide)
Ozempic belongs to a class of medications known as GLP-1 receptor agonists. Its primary function is to mimic the effects of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). GLP-1 plays a crucial role in regulating blood sugar levels and appetite. By activating the GLP-1 receptors, Ozempic promotes a sense of fullness, reduces food intake, and slows down the rate at which the stomach empties. Additionally, Ozempic helps the pancreas release insulin, which helps lower blood sugar levels. The combination of these effects contributes to weight loss in individuals with type 2 diabetes. Healthcare providers may also prescribe it off-label for patients who are overweight.
Read "How to Get Ozempic"
Wegovy (Semaglutide 2.4 mg)
Similar to Ozempic, Wegovy is also a GLP-1 receptor agonist and contains semaglutide as its active ingredient. However, Wegovy is specifically designed for weight management and is FDA-approved for use in individuals without diabetes. The higher maximum dose of semaglutide in Wegovy (2.4 mg) compared to the dose used for diabetes treatment contributes to its effectiveness in promoting weight loss over time. By influencing appetite and slowing down digestion, Wegovy aids individuals in reducing caloric intake and achieving sustainable weight loss.
Mounjaro (Tirzepatide)
Mounjaro is another GLP-1 receptor agonist, but it also acts on another hormone called glucose-dependent insulinotropic polypeptide (GIP). This dual action enhances the overall metabolic effect, leading to improved blood sugar control and weight loss. Like Ozempic and Wegovy, Mounjaro works by increasing feelings of fullness, reducing food intake, and slowing down digestion. The combination of these effects makes it a promising option for those seeking comprehensive metabolic and weight management.
Zepbound (Tirzepatide)
Zepbound was just approved for weight loss in November 2023. Unlike Wegovy, which has a higher maximum dose than Ozempic, Zepbound and Mounjaro are essentially the same. The only difference is that Zepbound is approved for weight loss and Mounjaro is approved for diabetes. These approvals may make one or the other more likely to be covered by insurance depending on your condition.
Compound Semaglutide & Tirzepatide
Semaglutide is the active ingredient in Ozempic & Wegovy. Tirzepatide is the active ingredient in Mounjaro and Zepbound. Zealthy sources these compound medications from reputable compounding pharmacies with National Association of Boards of Pharmacy Accreditation that are monitored by multiple government entities. The FDA allows compounded versions of GLP-1 medications due to shortages. They typically cost much less than the brand name medications when paying out-of-pocket - often 80% less expensive.
Read about Compound Semaglutide or Compound Tirzepatide
Metformin
Metformin is a well-established medication commonly used to treat type 2 diabetes. While its primary role is to improve insulin sensitivity and reduce glucose production in the liver, some individuals may experience weight loss as a side effect. Metformin does not directly target appetite or the digestive system but rather improves the body's response to insulin, leading to better blood sugar control. The weight loss observed with metformin is generally modest compared to the GLP-1 receptor agonists.
Key Differences Overall
- FDA Approval: Ozempic, Mounjaro & Metformin are FDA-approved for treatment of diabetes; Wegovy & Zepbound are FDA-approved for weight loss. Compound semaglutide & tirzepatide through Zealthy are not FDA-approved, however they are manufactured in US-based, NABP-accredited compounding facilities that are regularly inspected. Your Zealthy doctor and coordinators can help you determine which is right for you.
- Cost: Ozempic, Wegovy, Mounjaro & Zepbound may be covered by insurance depending on your condition. If they are, the cost can be as little as $0. If not covered, they typically cost over $1,000/month. Compound semaglutide is not covered by insurance, but costs as little as $151/month with Zealthy. Compound tirzepatide is also not covered by insurance and costs as little as $216/month with Zealthy when purchased quarterly. Metformin is often covered by insurance and is included with your Zealthy weight loss membership.
- Mechanism of Action: GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound influence appetite and digestion directly. Mounjaro & Zepbound are also GIP receptor agonists, which increase insulin levels and, paired with GLP-1 receptor agonists, can provide enhanced weight loss benefits. Metformin, on the other hand, improves insulin sensitivity and glucose metabolism without directly impacting appetite.
Zealthy's weight loss program is designed to help you lose weight with or without insurance. Once our healthcare providers review your information and determine you qualify for weight loss medication, our coordinators can work to get your medication covered by insurance or can recommend semaglutide or tirzepatide and have it shipped to you.
.svg)
.svg)
.svg)
.svg)